Please login to the form below

Stelara

This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.

J&J inks $6.5bn all-cash deal to acquire Momenta

J&J already has high stakes in the autoimmune disease market, with some of its existing products, including psoriasis med Stelara (ustekinumab), already reaching blockbuster status.

Latest news

J&J splashes $750m on anti-inflammatory drug bermekimab

J&J already has high stakes in the anti-inflammatory market, with its blockbuster IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab) and follow-up Tremfya (guselkumab). ... The therapy is a follow-up to its older blockbuster Stelara, which is facing
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

This includes a recent phase 3 BE VIVID study comparing the drug to Johnson &Johnson’s Stelara (ustekinumab), which bimekizumab also demonstrated superiority over.
Janssen files Tremfya for psoriatic arthritis in Europe

First approved in Europe two years ago, Tremfya (guselkumab) is the follow-up to J&J’s IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab), which is facing increased competition across ... of Stelara – which made $4.66bn in the first three
CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

showed it was better at clearing skin than placebo and Johnson &Johnson’s big-selling Stelara (ustekinumab) product.
Litigation concerns threaten to overshadow solid quarter at J&J

Growth for immunology therapy Stelara (ustekinumab) and blood cancer drugs Imbruvica (ibrutinib) and Darzalex (daratumumab) – plus Stelara follow-up Tremfya (guselkumab) – outweighed the effect of generic competition to older prostate cancer

More from news
Approximately 15 fully matching, plus 73 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were
Taking a strategic approach

Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for
Back to the future

Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

Why are new medicinal products denied reimbursement in France?

Haute Autorité De Sante. 2017. Available at: https://www.has-sante.fr/portail/upload/docs/application/pdf/2017-11/stelara_mc_summary_ct15850.pdf [Accessed 20 December 2018].

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account Executive: Competitive Salary

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Editorial Traffic Manager, Medical Communications Agency, London...: up to £45K

Medical Writers (All levels) Editorial / Scientific Leads & ...: Highly Competitive Remuneration packages

Account Management: Competitive Salary Offered

Medical Editor: Competitive Salary

Associate Account Director: Competitive Salary

Account Manager: Competitive Salary

Senior & Principal Medical Writers Medical Communications - ...: Salary TBC

Head of Strategic Planning, Healthcare Advertising/ Brand comms,...: Six figure salary

Group Account Director, Healthcare Advertising/ Brand comms, Lon...: 8 month contract up to £90K

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Senior Medical Writer: Competitive Salary

Publications Director: Competitive Salary

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior Account Manager/ Account Director: Competitive Salary Offered

Account Manager - Creative Healthcare Communications - South Wes...: Excellent Remuneration

Senior & Principal Medical Writer: Competitive Salary Offered

PMHub

Add my company

Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency: There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown: Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it: If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....

Email:
Password:

Please login to the form below

Stelara

COVID-19 Updates and Daily News

Featured jobs

Quick links